ID   ASAH2_RAT               Reviewed;         761 AA.
AC   Q91XT9;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2001, sequence version 1.
DT   02-OCT-2024, entry version 127.
DE   RecName: Full=Neutral ceramidase {ECO:0000305};
DE            Short=N-CDase;
DE            Short=NCDase;
DE            EC=3.5.1.- {ECO:0000269|PubMed:10488143, ECO:0000269|PubMed:11328816};
DE            EC=3.5.1.23 {ECO:0000269|PubMed:10488143, ECO:0000269|PubMed:11278489, ECO:0000269|PubMed:11328816, ECO:0000269|PubMed:15123644, ECO:0000269|PubMed:15217782};
DE   AltName: Full=Acylsphingosine deacylase 2;
DE   AltName: Full=N-acylsphingosine amidohydrolase 2;
DE   Contains:
DE     RecName: Full=Neutral ceramidase soluble form {ECO:0000305|PubMed:12499379};
GN   Name=Asah2;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 223-245; 261-273; 601-619
RP   AND 701-729, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES,
RP   GLYCOSYLATION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=11328816; DOI=10.1074/jbc.m102233200;
RA   Mitsutake S., Tani M., Okino N., Mori K., Ichinose S., Omori A., Iida H.,
RA   Nakamura T., Ito M.;
RT   "Purification, characterization, molecular cloning, and subcellular
RT   distribution of neutral ceramidase of rat kidney.";
RL   J. Biol. Chem. 276:26249-26259(2001).
RN   [2]
RP   PROTEIN SEQUENCE OF 80-100, SUBCELLULAR LOCATION, TOPOLOGY, GLYCOSYLATION,
RP   MUTAGENESIS OF SER-44; 50-SER--THR-71 AND SER-77, AND PROTEOLYTIC CLEAVAGE
RP   AFTER ASN-79.
RX   PubMed=12499379; DOI=10.1074/jbc.m207932200;
RA   Tani M., Iida H., Ito M.;
RT   "O-glycosylation of mucin-like domain retains the neutral ceramidase on the
RT   plasma membranes as a type II integral membrane protein.";
RL   J. Biol. Chem. 278:10523-10530(2003).
RN   [3]
RP   PROTEIN SEQUENCE OF 311-327; 635-648 AND 737-753.
RX   PubMed=10781606; DOI=10.1074/jbc.m002522200;
RA   El Bawab S., Roddy P., Qian T., Bielawska A., Lemasters J.J., Hannun Y.A.;
RT   "Molecular cloning and characterization of a human mitochondrial
RT   ceramidase.";
RL   J. Biol. Chem. 275:21508-21513(2000).
RN   [4]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10488143; DOI=10.1074/jbc.274.39.27948;
RA   El Bawab S., Bielawska A., Hannun Y.A.;
RT   "Purification and characterization of a membrane-bound nonlysosomal
RT   ceramidase from rat brain.";
RL   J. Biol. Chem. 274:27948-27955(1999).
RN   [5]
RP   TISSUE SPECIFICITY.
RX   PubMed=11330410; DOI=10.1023/a:1010792031910;
RA   Lundgren P., Nilsson A., Duan R.D.;
RT   "Distribution and properties of neutral ceramidase activity in rat
RT   intestinal tract.";
RL   Dig. Dis. Sci. 46:765-772(2001).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND ACTIVITY
RP   REGULATION.
RX   PubMed=11278489; DOI=10.1074/jbc.m009331200;
RA   El Bawab S., Birbes H., Roddy P., Szulc Z.M., Bielawska A., Hannun Y.A.;
RT   "Biochemical characterization of the reverse activity of rat brain
RT   ceramidase. A CoA-independent and fumonisin B1-insensitive ceramide
RT   synthase.";
RL   J. Biol. Chem. 276:16758-16766(2001).
RN   [7]
RP   INDUCTION.
RX   PubMed=11457826; DOI=10.1074/jbc.m102153200;
RA   Franzen R., Pautz A., Braeutigam L., Geisslinger G., Pfeilschifter J.,
RA   Huwiler A.;
RT   "Interleukin-1beta induces chronic activation and de novo synthesis of
RT   neutral ceramidase in renal mesangial cells.";
RL   J. Biol. Chem. 276:35382-35389(2001).
RN   [8]
RP   PHOSPHORYLATION.
RX   PubMed=12359735; DOI=10.1074/jbc.m204034200;
RA   Franzen R., Fabbro D., Aschrafi A., Pfeilschifter J., Huwiler A.;
RT   "Nitric oxide induces degradation of the neutral ceramidase in rat renal
RT   mesangial cells and is counterregulated by protein kinase C.";
RL   J. Biol. Chem. 277:46184-46190(2002).
RN   [9]
RP   UBIQUITINATION.
RX   PubMed=12482609; DOI=10.1016/s0014-5793(02)03727-4;
RA   Franzen R., Pfeilschifter J., Huwiler A.;
RT   "Nitric oxide induces neutral ceramidase degradation by the
RT   ubiquitin/proteasome complex in renal mesangial cell cultures.";
RL   FEBS Lett. 532:441-444(2002).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, GLYCOSYLATION,
RP   MUTAGENESIS OF PHE-756; GLU-757 AND ILE-758, AND REGION.
RX   PubMed=15123644; DOI=10.1074/jbc.m404012200;
RA   Tani M., Okino N., Sueyoshi N., Ito M.;
RT   "Conserved amino acid residues in the COOH-terminal tail are indispensable
RT   for the correct folding and localization and enzyme activity of neutral
RT   ceramidase.";
RL   J. Biol. Chem. 279:29351-29358(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY, FUNCTION, CATALYTIC ACTIVITY, PATHWAY,
RP   AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=15217782; DOI=10.1152/ajpgi.00155.2004;
RA   Olsson M., Duan R.-D., Ohlsson L., Nilsson A.;
RT   "Rat intestinal ceramidase: purification, properties, and physiological
RT   relevance.";
RL   Am. J. Physiol. 287:G929-G937(2004).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21613224; DOI=10.1074/jbc.m110.214866;
RA   Novgorodov S.A., Wu B.X., Gudz T.I., Bielawski J., Ovchinnikova T.V.,
RA   Hannun Y.A., Obeid L.M.;
RT   "Novel pathway of ceramide production in mitochondria: thioesterase and
RT   neutral ceramidase produce ceramide from sphingosine and acyl-CoA.";
RL   J. Biol. Chem. 286:25352-25362(2011).
CC   -!- FUNCTION: Plasma membrane ceramidase that hydrolyzes sphingolipid
CC       ceramides into sphingosine and free fatty acids at neutral pH
CC       (PubMed:10488143, PubMed:11328816, PubMed:15217782). Ceramides,
CC       sphingosine, and its phosphorylated form sphingosine-1-phosphate are
CC       bioactive lipids that mediate cellular signaling pathways regulating
CC       several biological processes including cell proliferation, apoptosis
CC       and differentiation (PubMed:11328816). Also catalyzes the reverse
CC       reaction allowing the synthesis of ceramides from fatty acids and
CC       sphingosine (PubMed:11278489, PubMed:15123644). Together with
CC       sphingomyelinase, participates in the production of sphingosine and
CC       sphingosine-1-phosphate from the degradation of sphingomyelin, a
CC       sphingolipid enriched in the plasma membrane of cells
CC       (PubMed:15217782). Also participates in the hydrolysis of ceramides
CC       from the extracellular milieu allowing the production of sphingosine-1-
CC       phosphate inside and outside cells. This is the case for instance with
CC       the digestion of dietary sphingolipids in the intestinal tract (By
CC       similarity). {ECO:0000250|UniProtKB:Q9JHE3,
CC       ECO:0000269|PubMed:10488143, ECO:0000269|PubMed:11278489,
CC       ECO:0000269|PubMed:11328816, ECO:0000269|PubMed:15123644,
CC       ECO:0000269|PubMed:15217782, ECO:0000303|PubMed:11328816}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=an N-acylsphing-4-enine + H2O = a fatty acid + sphing-4-enine;
CC         Xref=Rhea:RHEA:20856, ChEBI:CHEBI:15377, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:52639, ChEBI:CHEBI:57756; EC=3.5.1.23;
CC         Evidence={ECO:0000269|PubMed:10488143, ECO:0000269|PubMed:11278489,
CC         ECO:0000269|PubMed:11328816, ECO:0000269|PubMed:15123644,
CC         ECO:0000269|PubMed:15217782};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20857;
CC         Evidence={ECO:0000250|UniProtKB:Q9JHE3};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-hexadecanoylsphing-4-enine = hexadecanoate + sphing-4-
CC         enine; Xref=Rhea:RHEA:38891, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:57756, ChEBI:CHEBI:72959;
CC         Evidence={ECO:0000269|PubMed:10488143, ECO:0000269|PubMed:11278489,
CC         ECO:0000269|PubMed:11328816, ECO:0000269|PubMed:15217782};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38892;
CC         Evidence={ECO:0000250|UniProtKB:Q9JHE3};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:38893;
CC         Evidence={ECO:0000305|PubMed:11278489};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-tetradecanoylsphing-4-enine = sphing-4-enine +
CC         tetradecanoate; Xref=Rhea:RHEA:41287, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:30807, ChEBI:CHEBI:57756, ChEBI:CHEBI:72957;
CC         Evidence={ECO:0000269|PubMed:11278489};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:41289;
CC         Evidence={ECO:0000305|PubMed:11278489};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(9Z-octadecenoyl)-sphing-4-enine = (9Z)-octadecenoate
CC         + sphing-4-enine; Xref=Rhea:RHEA:41299, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:30823, ChEBI:CHEBI:57756, ChEBI:CHEBI:77996;
CC         Evidence={ECO:0000269|PubMed:11278489};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41300;
CC         Evidence={ECO:0000250|UniProtKB:Q9NR71};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:41301;
CC         Evidence={ECO:0000305|PubMed:11278489};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(15Z-tetracosenoyl)-sphing-4-enine = (15Z)-
CC         tetracosenoate + sphing-4-enine; Xref=Rhea:RHEA:41267,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:32392, ChEBI:CHEBI:57756,
CC         ChEBI:CHEBI:74450; Evidence={ECO:0000269|PubMed:11278489};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:41269;
CC         Evidence={ECO:0000305|PubMed:11278489};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-octanoylsphing-4-enine = octanoate + sphing-4-enine;
CC         Xref=Rhea:RHEA:45092, ChEBI:CHEBI:15377, ChEBI:CHEBI:25646,
CC         ChEBI:CHEBI:45815, ChEBI:CHEBI:57756;
CC         Evidence={ECO:0000269|PubMed:11328816, ECO:0000269|PubMed:15217782};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45093;
CC         Evidence={ECO:0000250|UniProtKB:Q9NR71};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-dodecanoylsphing-4-enine = dodecanoate + sphing-4-
CC         enine; Xref=Rhea:RHEA:41291, ChEBI:CHEBI:15377, ChEBI:CHEBI:18262,
CC         ChEBI:CHEBI:57756, ChEBI:CHEBI:72956;
CC         Evidence={ECO:0000269|PubMed:11328816, ECO:0000269|PubMed:15123644};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41292;
CC         Evidence={ECO:0000250|UniProtKB:Q9JHE3};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:41293;
CC         Evidence={ECO:0000250|UniProtKB:Q9JHE3};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(hexanoyl)sphing-4-enine = hexanoate + sphing-4-enine;
CC         Xref=Rhea:RHEA:41295, ChEBI:CHEBI:15377, ChEBI:CHEBI:17120,
CC         ChEBI:CHEBI:57756, ChEBI:CHEBI:63867;
CC         Evidence={ECO:0000250|UniProtKB:Q9NR71};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41296;
CC         Evidence={ECO:0000250|UniProtKB:Q9NR71};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-octadecanoylsphing-4-enine = octadecanoate + sphing-4-
CC         enine; Xref=Rhea:RHEA:41279, ChEBI:CHEBI:15377, ChEBI:CHEBI:25629,
CC         ChEBI:CHEBI:57756, ChEBI:CHEBI:72961;
CC         Evidence={ECO:0000250|UniProtKB:Q9JHE3};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41280;
CC         Evidence={ECO:0000250|UniProtKB:Q9JHE3};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=hexadecanoate + sphinganine = H2O + N-hexadecanoylsphinganine;
CC         Xref=Rhea:RHEA:43440, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:57817, ChEBI:CHEBI:67042;
CC         Evidence={ECO:0000269|PubMed:10488143, ECO:0000269|PubMed:11328816};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:43442;
CC         Evidence={ECO:0000250|UniProtKB:Q9JHE3};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + N-(octadecanoyl)-sphinganine = octadecanoate +
CC         sphinganine; Xref=Rhea:RHEA:45008, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:25629, ChEBI:CHEBI:57817, ChEBI:CHEBI:67033;
CC         Evidence={ECO:0000269|PubMed:11328816};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45009;
CC         Evidence={ECO:0000250|UniProtKB:Q9JHE3};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000250|UniProtKB:Q9NR71};
CC       Note=Binds 1 zinc ion per subunit. {ECO:0000250|UniProtKB:Q9NR71};
CC   -!- ACTIVITY REGULATION: The reverse reaction is inhibited by Zn(2+) and
CC       Cu(2+) (PubMed:11278489). Inhibited by cardiolipin and phosphatidic
CC       acid (PubMed:11278489). {ECO:0000269|PubMed:11278489}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=71.4 uM for N-(octanoyl)-sphing-4-enine
CC         {ECO:0000269|PubMed:15217782};
CC         KM=66 uM for N-hexadecanoylsphing-4-enine
CC         {ECO:0000269|PubMed:15217782};
CC         Vmax=160 umol/min/mg enzyme with N-(octanoyl)-sphing-4-enine as
CC         substrate {ECO:0000269|PubMed:15217782};
CC         Vmax=16 umol/min/mg enzyme with N-hexadecanoylsphing-4-enine as
CC         substrate {ECO:0000269|PubMed:15217782};
CC         Vmax=4.4 umol/min/mg enzyme with N-hexadecanoylsphing-4-enine as
CC         substrate {ECO:0000269|PubMed:10488143};
CC         Vmax=1.2 umol/min/mg enzyme with dihydroceramide as substrate
CC         {ECO:0000269|PubMed:10488143};
CC         Vmax=0.63 umol/min/mg enzyme toward tetradecanoate for the synthesis
CC         of N-tetradecanoylsphing-4-enine (at pH 7.0)
CC         {ECO:0000269|PubMed:11278489};
CC         Vmax=0.47 umol/min/mg enzyme toward hexadecanoate for the synthesis
CC         of N-hexadecanoylsphing-4-enine (at pH 7.0)
CC         {ECO:0000269|PubMed:11278489};
CC         Vmax=0.28 umol/min/mg enzyme toward (9Z)-octadecenoate for the
CC         synthesis of N-(9Z-octadecenoyl)-sphing-4-enine (at pH 7.0)
CC         {ECO:0000269|PubMed:11278489};
CC         Vmax=0.25 umol/min/mg enzyme toward (15Z)-tetracosenoate for the
CC         synthesis of N-(15Z-tetracosenoyl)sphing-4-enine (at pH 7.0)
CC         {ECO:0000269|PubMed:11278489};
CC         Vmax=0.3 umol/min/mg enzyme toward D-erythro-sphing-4-enine for the
CC         synthesis of N-hexadecanoylsphing-4-enine (at pH 7.0)
CC         {ECO:0000269|PubMed:11278489};
CC         Note=More efficiently hydrolyzes N-lauroylsphingosine/C12:0-ceramides
CC         compared to N-palmitoylsphingosine/C16:0-ceramides and N-
CC         stearoylsphingosine/C18:0-ceramides (PubMed:11328816). The catalytic
CC         efficiency towards dihydroceramides and phytoceramides is very low
CC         (PubMed:10488143, PubMed:11328816). For the reverse synthetic
CC         reaction exhibits a higher activity with D-erythro-sphing-4-enine and
CC         the fatty acid tetradecanoate as substrates (PubMed:11278489).
CC         {ECO:0000269|PubMed:10488143, ECO:0000269|PubMed:11278489,
CC         ECO:0000269|PubMed:11328816};
CC       pH dependence:
CC         Optimum pH is 6-7 for N-hexadecanoylsphing-4-enine hydrolysis
CC         (PubMed:11328816). Optimum pH is 7-10 for N-hexadecanoylsphing-4-
CC         enine hydrolysis (PubMed:10488143). Optimum pH is 6-8 for N-
CC         (octanoyl)-sphing-4-enine hydrolysis (PubMed:15217782). Optimum pH is
CC         6.5-7 for hexadecanoate in the reverse reaction (PubMed:11278489).
CC         {ECO:0000269|PubMed:10488143, ECO:0000269|PubMed:11278489,
CC         ECO:0000269|PubMed:11328816, ECO:0000269|PubMed:15217782};
CC   -!- PATHWAY: Lipid metabolism; sphingolipid metabolism.
CC       {ECO:0000269|PubMed:15217782}.
CC   -!- SUBCELLULAR LOCATION: [Neutral ceramidase]: Cell membrane
CC       {ECO:0000269|PubMed:11328816, ECO:0000269|PubMed:12499379,
CC       ECO:0000269|PubMed:15123644}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:12499379}. Membrane raft
CC       {ECO:0000269|PubMed:11328816}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:12499379}. Membrane, caveola
CC       {ECO:0000250|UniProtKB:Q9JHE3}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:12499379}. Golgi apparatus membrane
CC       {ECO:0000250|UniProtKB:Q9NR71}; Single-pass type II membrane protein
CC       {ECO:0000269|PubMed:12499379}. Mitochondrion
CC       {ECO:0000269|PubMed:21613224}. Secreted, extracellular exosome
CC       {ECO:0000250|UniProtKB:Q9NR71}. Note=Enriched in exosomes upon
CC       stimulation by cytokine (By similarity). Enriched in caveolae and lipid
CC       rafts (By similarity). The localization to the mitochondrion could not
CC       be confirmed (By similarity). {ECO:0000250|UniProtKB:Q9JHE3,
CC       ECO:0000250|UniProtKB:Q9NR71}.
CC   -!- SUBCELLULAR LOCATION: [Neutral ceramidase soluble form]: Secreted
CC       {ECO:0000269|PubMed:12499379, ECO:0000269|PubMed:15123644}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, kidney and heart
CC       (PubMed:11328816). Expressed at lower level in other tissues such as
CC       liver (PubMed:11328816). Expressed in intestine, kidney and liver (at
CC       protein level) (PubMed:11328816, PubMed:11330410). Localizes in the
CC       epithelia of the jejunum and ileum (PubMed:11330410).
CC       {ECO:0000269|PubMed:11328816, ECO:0000269|PubMed:11330410}.
CC   -!- INDUCTION: By interleukin-1-beta in renal mesangial cells.
CC       {ECO:0000269|PubMed:11457826}.
CC   -!- PTM: Proteolytic cleavage of the N-terminus removes the signal-anchor
CC       and produces a soluble form of the protein.
CC       {ECO:0000269|PubMed:12499379}.
CC   -!- PTM: N-glycosylated (PubMed:11328816, PubMed:15123644). Required for
CC       enzyme activity (PubMed:11328816). {ECO:0000269|PubMed:11328816,
CC       ECO:0000269|PubMed:15123644}.
CC   -!- PTM: O-glycosylated (PubMed:12499379). Required to retain it as a type
CC       II membrane protein at the cell surface (PubMed:12499379).
CC       {ECO:0000269|PubMed:12499379}.
CC   -!- PTM: Phosphorylated. May prevent ubiquitination and subsequent
CC       degradation. {ECO:0000269|PubMed:12359735,
CC       ECO:0000269|PubMed:12482609}.
CC   -!- PTM: Ubiquitinated, leading to its degradation by the proteasome.
CC       Ubiquitination is triggered by nitric oxide.
CC       {ECO:0000269|PubMed:12482609}.
CC   -!- SIMILARITY: Belongs to the neutral ceramidase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB057433; BAB62033.1; -; mRNA.
DR   RefSeq; NP_446098.1; NM_053646.2.
DR   RefSeq; XP_006231325.1; XM_006231263.1.
DR   RefSeq; XP_006231330.1; XM_006231268.3.
DR   RefSeq; XP_006231332.1; XM_006231270.1.
DR   RefSeq; XP_008758542.1; XM_008760320.2.
DR   RefSeq; XP_017444135.1; XM_017588646.1.
DR   RefSeq; XP_017444136.1; XM_017588647.1.
DR   RefSeq; XP_017444137.1; XM_017588648.1.
DR   RefSeq; XP_017444138.1; XM_017588649.1.
DR   RefSeq; XP_017444139.1; XM_017588650.1.
DR   RefSeq; XP_017444140.1; XM_017588651.1.
DR   AlphaFoldDB; Q91XT9; -.
DR   SMR; Q91XT9; -.
DR   STRING; 10116.ENSRNOP00000073116; -.
DR   SwissLipids; SLP:000000682; -.
DR   GlyCosmos; Q91XT9; 16 sites, No reported glycans.
DR   GlyGen; Q91XT9; 17 sites, 1 N-linked glycan (1 site).
DR   iPTMnet; Q91XT9; -.
DR   PhosphoSitePlus; Q91XT9; -.
DR   PaxDb; 10116-ENSRNOP00000016688; -.
DR   Ensembl; ENSRNOT00000077135.2; ENSRNOP00000073116.1; ENSRNOG00000012196.6.
DR   Ensembl; ENSRNOT00055051085; ENSRNOP00055042083; ENSRNOG00055029490.
DR   Ensembl; ENSRNOT00060051120; ENSRNOP00060042530; ENSRNOG00060029443.
DR   Ensembl; ENSRNOT00065050687; ENSRNOP00065041660; ENSRNOG00065029336.
DR   GeneID; 114104; -.
DR   KEGG; rno:114104; -.
DR   UCSC; RGD:69410; rat.
DR   AGR; RGD:69410; -.
DR   CTD; 56624; -.
DR   RGD; 69410; Asah2.
DR   eggNOG; KOG2232; Eukaryota.
DR   GeneTree; ENSGT00390000015792; -.
DR   InParanoid; Q91XT9; -.
DR   OMA; VVEINMM; -.
DR   OrthoDB; 999732at2759; -.
DR   PhylomeDB; Q91XT9; -.
DR   BRENDA; 3.5.1.23; 5301.
DR   Reactome; R-RNO-9840310; Glycosphingolipid catabolism.
DR   SABIO-RK; Q91XT9; -.
DR   UniPathway; UPA00222; -.
DR   PRO; PR:Q91XT9; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000012196; Expressed in duodenum and 18 other cell types or tissues.
DR   GO; GO:0005901; C:caveola; ISS:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; IBA:GO_Central.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0102121; F:ceramidase activity; IEA:UniProtKB-EC.
DR   GO; GO:0071633; F:dihydroceramidase activity; IDA:UniProtKB.
DR   GO; GO:0017040; F:N-acylsphingosine amidohydrolase activity; IDA:UniProtKB.
DR   GO; GO:0070774; F:phytoceramidase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; ISO:RGD.
DR   GO; GO:0046513; P:ceramide biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0046514; P:ceramide catabolic process; IDA:UniProtKB.
DR   GO; GO:0006672; P:ceramide metabolic process; ISS:UniProtKB.
DR   GO; GO:0044241; P:lipid digestion; ISS:UniProtKB.
DR   GO; GO:0042759; P:long-chain fatty acid biosynthetic process; IBA:GO_Central.
DR   GO; GO:2001234; P:negative regulation of apoptotic signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007346; P:regulation of mitotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0046512; P:sphingosine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006670; P:sphingosine metabolic process; ISS:UniProtKB.
DR   Gene3D; 2.60.40.2300; Neutral/alkaline non-lysosomal ceramidase, C-terminal domain; 1.
DR   InterPro; IPR006823; Ceramidase_alk.
DR   InterPro; IPR038445; NCDase_C_sf.
DR   InterPro; IPR031331; NEUT/ALK_ceramidase_C.
DR   InterPro; IPR031329; NEUT/ALK_ceramidase_N.
DR   PANTHER; PTHR12670; CERAMIDASE; 1.
DR   PANTHER; PTHR12670:SF1; NEUTRAL CERAMIDASE; 1.
DR   Pfam; PF04734; Ceramidase_alk; 1.
DR   Pfam; PF17048; Ceramidse_alk_C; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; Calcium; Cell membrane; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Golgi apparatus; Hydrolase; Lipid metabolism;
KW   Membrane; Metal-binding; Mitochondrion; Phosphoprotein; Reference proteome;
KW   Secreted; Signal-anchor; Sphingolipid metabolism; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Zinc.
FT   CHAIN           1..761
FT                   /note="Neutral ceramidase"
FT                   /id="PRO_0000247103"
FT   CHAIN           80..761
FT                   /note="Neutral ceramidase soluble form"
FT                   /evidence="ECO:0000269|PubMed:12499379"
FT                   /id="PRO_0000247104"
FT   TOPO_DOM        1..11
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        12..32
FT                   /note="Helical; Signal-anchor for type II membrane protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        33..761
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000255"
FT   REGION          43..76
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          751..761
FT                   /note="Required for correct folding and localization"
FT                   /evidence="ECO:0000269|PubMed:15123644"
FT   ACT_SITE        335
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250"
FT   BINDING         115
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   BINDING         175
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   BINDING         284
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   BINDING         521
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   BINDING         560
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   BINDING         693
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   BINDING         695
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   BINDING         698
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   SITE            79..80
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000269|PubMed:12499379"
FT   CARBOHYD        51
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        52
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        56
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        57
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        58
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        60
FT                   /note="O-linked (GalNAc...) serine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        61
FT                   /note="O-linked (GalNAc...) serine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        63
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        64
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        66
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        68
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        69
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        71
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        198
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        412
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        449
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        343..357
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   DISULFID        350..365
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   DISULFID        429..479
FT                   /evidence="ECO:0000250|UniProtKB:Q9NR71"
FT   MUTAGEN         44
FT                   /note="S->A: Abolishes O-glycosylation and localization at
FT                   the cell surface; when associated with A-50; A-51; A-52; A-
FT                   56; A-57; A-58; A-60; A-61; A-62; A-63; A-65; A-76; A-68;
FT                   A-69; A-71 and A-77."
FT                   /evidence="ECO:0000269|PubMed:12499379"
FT   MUTAGEN         50..71
FT                   /note="STTQGPTTTQSSPTTQTPTTQT->AAAQGPAAAQAAPAAQAPAAQA:
FT                   Abolishes O-glycosylation and localization at the cell
FT                   surface; when associated with A-44 and A-77."
FT                   /evidence="ECO:0000269|PubMed:12499379"
FT   MUTAGEN         77
FT                   /note="S->A: Abolishes O-glycosylation and localization at
FT                   the cell surface; when associated with A-44; A-50; A-51; A-
FT                   52; A-56; A-57; A-58; A-60; A-61; A-62; A-63; A-65; A-76;
FT                   A-68; A-69 and A-71."
FT                   /evidence="ECO:0000269|PubMed:12499379"
FT   MUTAGEN         756
FT                   /note="F->I: No effect."
FT                   /evidence="ECO:0000269|PubMed:15123644"
FT   MUTAGEN         756
FT                   /note="F->R,D: Loss of function."
FT                   /evidence="ECO:0000269|PubMed:15123644"
FT   MUTAGEN         757
FT                   /note="E->R: No effect."
FT                   /evidence="ECO:0000269|PubMed:15123644"
FT   MUTAGEN         758
FT                   /note="I->F: Impairs enzyme activity."
FT                   /evidence="ECO:0000269|PubMed:15123644"
FT   MUTAGEN         758
FT                   /note="I->R,D: Loss of function."
FT                   /evidence="ECO:0000269|PubMed:15123644"
FT   MUTAGEN         758
FT                   /note="I->V: No effect."
FT                   /evidence="ECO:0000269|PubMed:15123644"
FT   CONFLICT        325
FT                   /note="G -> N (in Ref. 3; AA sequence)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   761 AA;  83488 MW;  68B91BC78AEB6324 CRC64;
     MAKRTFSSLE AFLIFLLVMM TAITVALLTL LFVTSGTIEN HKDSGNHWVS TTQGPTTTQS
     SPTTQTPTTQ TPDLPPSQNF SGYYIGVGRA DCTGQVSDIN LMGYGKNGQN AQGLLTRLFS
     RAFILADPDG SNRMAFVSVE LCMISQRLRL EVLKRLQSKY GSLYRRDNVI LSATHTHSGP
     AGFFQYTLYI LASEGFSNRT FQYIVSGIVK SIDIAHTNLK PGKVLINKGN VANVQINRSP
     SSYLQNPPSE RARYSSDTDK EMVVLKLVDL NGEDLGLISW FAVHPVSMNN SNHLVNSDNM
     GYAAYLFEQE KNRGYLPGQG PFVAGFASSN LGDVSPNILG PHCVNTGESC DNDKSTCPSG
     GPSMCMASGP GQDMFESTHI IGRVIYQKAK ELHASASQEV TGPVLTAHQW VNMTDVSVQL
     NATHTVKTCK AALGYSFAAG TIDGVSGLNI TQGTTEGNLF WDTLRDQLLG KPSEEIIECQ
     KPKPILIHTG ELTKPHPWQP DIVDIQIVTL GSLAIAAIPG EFTTMSGRRL REAVKKEFAL
     YGMKDMTVVI AGLSNVYTHY ITTYEEYQAQ RYEAASTIYG PHTLSAYIQL FRALAKAIAT
     DTVANMSSGP EPPFFKNLIG SLIPNIADRA PIGKQFGDVL QPAKPEYRVG EVVEVVFVGA
     NPKNSAENQT HQTFLTVEKY EDSVANWQIM HNDASWETRF YWHKGVLGLS NATIHWHIPD
     TALPGVYRIR YFGHNRKQEL LKPAVILAFE GISSPFEIVT T
//
